B+
Bull case
25%
Probability
Target price
$330.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
IQV
IQVIAANYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The positive deterministic prior is supported by Q2 revenue growth of 8.7%, R&D Solutions bookings growth of 19%, 1.22x book-to-bill, and higher 2026 guidance. If Q3 confirms backlog conversion and continued commercial growth, the stock could approach the bull scenario.
Posture
Constructive
Lead driver
Value
What changed
Next scheduled catalyst: earnings 2026-10-27 · BMO.
What can break
Commercial Solutions relies on numerous third-party data suppliers; concentration and availability effects are undisclosed [#REL-c8fc4ab8-39dc-44ce-9255-96cd7fa29297]. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
Momentum
93
Value
63
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $302.00 · Bull $330.00 · Bear $240.00Analysis 2026-10-25; returns require an exact persisted reference.
Earnings
2026-10-27 · BMO
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-10-23 • Vendor: Data Vendor v1
Scores
As of 2026-10-23 • Model: HYBRID_IC_RP
AI Memo
As of 2026-10-25 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-10-23
Investment thesis
As of 2026-10-23
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-10-23. Definitions
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $304.71
Why
Momentum93 · Δ7d -4.2
Value63 · Δ7d -0.3
Sentiment55 · Δ7d +0.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Next scheduled catalyst: earnings 2026-10-27 · BMO.
- • Value remains the lead driver in the composite, 7D delta -0.3.
Contradictions & invalidation
- • Commercial Solutions relies on numerous third-party data suppliers; concentration and availability effects are undisclosed [#REL-c8fc4ab8-39dc-44ce-9255-96cd7fa29297]. Source: https://www.sec.gov/Archives/edgar/data/1478242/000162828026008322/iqv-20251231.htm
- • Explorer and Life Science Models have no disclosed incremental revenue or paid-adoption metrics [#IR-2026-10-07-EXPLORER] [#IR-2026-10-07-MODELS].
- • Bookings may convert more slowly than expected, margins or cash flow may disappoint, and the October product launches have no disclosed monetization.
Catalyst clock
2026-10-27 · BMO
October 27 Q3 results test R&D bookings conversion and raised guidance
Lead driver: Value · See fundamentals
Momentum
93
8% active weight
Current posture
7d trendSoftening
Δ7d
-4.2
Δ21d
+0.8
Value
63
47% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-1.0
Sentiment
55
45% active weight
Current posture
7d trendFlat
Δ7d
+0.8
Δ21d
-8.1
Why this grade
Composite grade A. Momentum 93.4 / Value 62.8 / Sentiment 55.1
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-10-25. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$302.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$240.00
Analysis reference price unavailable
Analysis 2026-10-25 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-10-23
Fundamentals (TTM)
As of 2026-10-23
Market Cap
$45.98B
Beta
1.37
Shares Out
164.6M
P/E (TTM)
32.2
P/S (TTM)
2.51
P/FCF (TTM)
18.07
Rev YoY
+8.8%
EPS YoY
-0.4%
Gross Margin
+26.0%
Op Margin
+13.9%
Net Debt
$14.12B
Current Ratio
0.71
As of 2026-10-23 • Updated nightlySource: Internal modelMethods & Data